血清生物学标志物在急性肠系膜缺血性疾病早期诊断中的研究进展  

Research progress of serum biomarkers in early diagnosis of acute mesenteric ischemic disease

作　　者：徐亮[1] 谭诗云[1] 李明[1] XU Liang;TAN Shiyun;LI Ming(Department of Gastroenterology,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院消化内科,湖北武汉430060

出　　处：《胃肠病学和肝病学杂志》2023年第6期693-697,共5页Chinese Journal of Gastroenterology and Hepatology

基　　金：国家自然科学基金(82004114)。

摘　　要：急性肠系膜缺血性疾病(acute mesenteric ischemia,AMI)是临床上一种十分危急且高死亡率的腹部急症。由于该病的临床症状和体征通常缺乏特异性,患者确诊时病情往往已进展至肠管并发生不可逆性坏死,最终导致临床病死率居高不下。近年来,尽管随着CT血管造影、数字减影血管造影等成像技术的发展使得AMI在诊断上具有更高的敏感度和特异度,但这是一种有创性检查并且通常需要经验丰富的放射科医师来解释检查结果。因此,寻找能够早期精确诊断AMI的客观、便捷、特异性的血清生物学标志物,对降低AMI病死率至关重要。本文总结国内外关于诊断AMI的经典、新型及其他血清生物标志物,为AMI的早期诊断提供依据。Acute mesenteric ischemic(AMI)is a very critical abdominal emergency with high mortality.Due to the lack of specificity of clinical symptoms and signs of the disease,patients are often diagnosed with irreversible intestinal necrosis,resulting in high clinical mortality.In recent years,although the development of CT angiography,digital subtraction angiography and other imaging techniques have made the diagnosis of AMI more sensitive and specific,they are invasive procedures and usually require skilled radiologists to interpret the examination results.Therefore,it is very important to find objective,convenient and specific serum biomarkers for early and accurate diagnosis of AMI to reduce the mortality of AMI.This article summarized the classical,new and other serum biomarkers for the diagnosis of AMI,and provided the basis for the early diagnosis of AMI.

关 键 词：急性肠系膜缺血性疾病 血清生物学标志物 早期诊断 

分 类 号：R572.3[医药卫生—消化系统]